Bayer triples sales forecast for prostate cancer drug Nubeqa
pharmaphorum
FEBRUARY 18, 2022
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.
Let's personalize your content